Levemir Innolet

Insulin detemir, the active ingredient in Levemir Innolet, is a long‑acting insulin analog presented as an injectable solution for subcutaneous administration. It is used to improve glycaemic control in adults and children with type 1 or type 2 diabetes mellitus.

GNH USA supplies Levemir Innolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory requirements and is manufactured under GMP conditions, ensuring consistent potency and safety for patients. It is distributed through a cold‑chain logistics network to maintain stability.

Levemir Innolet (insulin detemir) is a long‑acting insulin analog used in the management of diabetes mellitus.

- Type 1 diabetes mellitus: provides basal insulin to maintain fasting glucose levels. - Type 2 diabetes mellitus: complements oral agents or other insulin to achieve target glycaemic control. - Pediatric diabetes: supplies basal insulin for children who require long‑acting coverage.

Levemir Innolet may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight observed in some patients. - Lipodystrophy: localized changes in subcutaneous fat at injection sites.

Serious or Rare Side Effects: - Allergic reactions: urticaria, angioedema, or anaphylaxis requiring immediate medical attention. - Edema: peripheral swelling that may indicate fluid retention.

When using Levemir Innolet, consider the following precautions.

- Hypoglycemia risk: monitor blood glucose regularly and adjust dose as needed. - Renal impairment: use with caution; dose adjustment may be required. - Hepatic impairment: monitor liver function, as insulin metabolism can be altered. - Pregnancy and lactation: assess risk‑benefit and use only if clearly needed. - Drug interactions: review concomitant medications that may affect glucose levels. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Innolet can interact with other medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Concurrent sulfonylureas: increased risk of severe hypoglycemia. - Beta‑blockers: may mask hypoglycemia symptoms. - Systemic corticosteroids: may reduce insulin efficacy, requiring dose increase.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose levels. - ACE inhibitors: can potentiate hypoglycemia. - Oral contraceptives: may affect insulin requirements.